PL362148A1 - Leczenie żołądkowo-jelitowych guzów stromalnych - Google Patents

Leczenie żołądkowo-jelitowych guzów stromalnych

Info

Publication number: PL362148A1
Authority: PL; Poland
Prior art keywords: treatment; gastrointestinal stromal; stromal tumors; methylpiperazin; ylamino
Prior art date: 2000-10-27

Application number

PL36214801A

Other languages

English (en)

Other versions

PL209733B1 (pl

Inventor

Elisabeth Buchdunger

Renaud Capdeville

George Daniel Demetri

Sasa Dimitrijevic

Brian J. Druker

Jonathan A. Fletcher

Heikki Joensuu

Sandra Leta Silberman

David Tuveson

Michael C. Heinrich

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-27

Filing date

2001-10-26

Publication date

2004-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL362148(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-10-26 Application filed by Novartis Ag filed Critical Novartis Ag

2004-10-18 Publication of PL362148A1 publication Critical patent/PL362148A1/pl

2011-10-31 Publication of PL209733B1 publication Critical patent/PL209733B1/pl

Links

206010051066 Gastrointestinal stromal tumour Diseases 0.000 title abstract 2
201000011243 gastrointestinal stromal tumor Diseases 0.000 title abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Farming Of Fish And Shellfish (AREA)

PL362148A 2000-10-27 2001-10-26 Zastosowanie 4-(4-metylopiperazyno-1-ylometylo)-N-[4-metylo-3-(4-pirydyn-3-ylo)pirymidyn-2-yloamino)fenylo]benzamidu w leczeniu żołądkowo-jelitowych guzów podścieliskowych PL209733B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24381000P	2000-10-27	2000-10-27
PCT/EP2001/012442 WO2002034727A2 (en)	2000-10-27	2001-10-26	Treatment of gastrointestinal stromal tumors

Publications (2)

Publication Number	Publication Date
PL362148A1 true PL362148A1 (pl)	2004-10-18
PL209733B1 PL209733B1 (pl)	2011-10-31

Family

ID=22920224

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL362148A PL209733B1 (pl)	2000-10-27	2001-10-26	Zastosowanie 4-(4-metylopiperazyno-1-ylometylo)-N-[4-metylo-3-(4-pirydyn-3-ylo)pirymidyn-2-yloamino)fenylo]benzamidu w leczeniu żołądkowo-jelitowych guzów podścieliskowych

Country Status (25)

Country	Link
US (1)	US6958335B2 (pl)
EP (1)	EP1332137B1 (pl)
JP (1)	JP4386635B2 (pl)
KR (1)	KR100885129B1 (pl)
CN (1)	CN1276754C (pl)
AT (1)	ATE321556T1 (pl)
AU (2)	AU1826202A (pl)
BR (1)	BRPI0114870B8 (pl)
CA (1)	CA2424470C (pl)
CY (1)	CY1105055T1 (pl)
CZ (1)	CZ303944B6 (pl)
DE (1)	DE60118430T2 (pl)
DK (1)	DK1332137T3 (pl)
ES (1)	ES2260317T3 (pl)
HU (1)	HU229106B1 (pl)
IL (2)	IL155029A0 (pl)
MX (1)	MXPA03003703A (pl)
NO (1)	NO324948B1 (pl)
NZ (1)	NZ525254A (pl)
PL (1)	PL209733B1 (pl)
PT (1)	PT1332137E (pl)
RU (1)	RU2301066C2 (pl)
SK (1)	SK287335B6 (pl)
WO (1)	WO2002034727A2 (pl)
ZA (1)	ZA200302155B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
BR0209647A (pt) *	2001-05-16	2004-07-27	Novartis Ag	Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico
PT1401416E (pt) *	2001-06-29	2007-02-28	Ab Science	Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
US7700610B2 (en) *	2001-06-29	2010-04-20	Ab Science	Use of tyrosine kinase inhibitors for treating allergic diseases
EP1434991B1 (en) *	2001-06-29	2007-10-17	AB Science	New potent, selective and non toxic c-kit inhibitors
CA2452366A1 (en) *	2001-06-29	2003-01-16	Ab Science	Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
CA2452169A1 (en) *	2001-06-29	2003-01-09	Ab Science	Use of tyrosine kinase inhibitors for treating inflammatory diseases
CA2460845A1 (en) *	2001-09-20	2003-03-27	Ab Science	Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
WO2003035050A2 (en) *	2001-09-20	2003-05-01	Ab Science	Use of tyrosine kinase inhibitors for promoting hair growth
CA2477111A1 (en) *	2002-02-27	2003-09-04	Ab Science	Use of tyrosine kinase inhibitors for treating cns disorders
FR2844452A1 (fr) *	2002-09-18	2004-03-19	Inst Gustave Roussy Igr	Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7202257B2 (en)	2003-12-24	2007-04-10	Deciphera Pharmaceuticals, Llc	Anti-inflammatory medicaments
US7144911B2 (en)	2002-12-31	2006-12-05	Deciphera Pharmaceuticals Llc	Anti-inflammatory medicaments
US7279576B2 (en)	2002-12-31	2007-10-09	Deciphera Pharmaceuticals, Llc	Anti-cancer medicaments
CN100467064C (zh) *	2003-09-19	2009-03-11	诺瓦提斯公司	伊马替尼和米哚妥林在制备治疗胃肠道基质肿瘤药物中的应用
US20100210596A1 (en) *	2006-02-01	2010-08-19	Bluestone Jeffrey A	Use of aminopyrimidine compounds in the treatment of immune disorders
US20080221132A1 (en) *	2006-09-11	2008-09-11	Xiong Cai	Multi-Functional Small Molecules as Anti-Proliferative Agents
CA2662580C (en) *	2006-09-11	2013-05-21	Curis, Inc.	Tyrosine kinase inhibitors containing a zinc binding moiety
US8642067B2 (en)	2007-04-02	2014-02-04	Allergen, Inc.	Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) *	2007-09-26	2009-03-26	Protia, Llc	Deuterium-enriched imatinib
CN101584696A (zh)	2008-05-21	2009-11-25	上海艾力斯医药科技有限公司	包含喹唑啉衍生物的组合物及制备方法、用途
WO2010120386A1 (en)	2009-04-17	2010-10-21	Nektar Therapeutics	Oligomer-protein tyrosine kinase inhibitor conjugates
KR102061743B1 (ko)	2011-03-04	2020-01-03	뉴젠 세러퓨틱스 인코포레이티드	알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
CN102918029B (zh)	2011-05-17	2015-06-17	江苏康缘药业股份有限公司	4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
EP2817030A1 (en)	2012-02-21	2014-12-31	Ranbaxy Laboratories Limited	Stable dosage forms of imatinib mesylate
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP2877159B8 (en)	2012-07-27	2018-02-14	Izumi Technology, LLC.	Efflux inhibitor compositions and methods of treatment using the same
JP6799201B2 (ja)	2013-07-31	2020-12-16	アヴァリンファーマインク．	エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US11285152B2 (en)	2017-07-20	2022-03-29	Kashiv Biosciences, Llc	Stable oral pharmaceutical composition of imatinib
AU2019216351B2 (en)	2018-01-31	2024-07-25	Deciphera Pharmaceuticals, Llc	Combination therapy for the treatment of mastocytosis
EP3746059B1 (en)	2018-01-31	2026-03-04	Deciphera Pharmaceuticals, LLC	Combination therapy for the treatment of gastrointestinal stromal tumors
WO2020185812A1 (en)	2019-03-11	2020-09-17	Teva Pharmaceuticals International Gmbh	Solid state forms of ripretinib
EP4725489A2 (en)	2019-08-02	2026-04-15	OneHealthCompany, Inc.	Treatment of canine cancers
TWI878335B (zh)	2019-08-12	2025-04-01	美商迪賽孚爾製藥有限公司	治療胃腸道基質瘤方法
FI4013412T3 (fi)	2019-08-12	2026-03-24	Deciphera Pharmaceuticals Llc	Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
AU2020419197B2 (en)	2019-12-30	2023-08-31	Deciphera Pharmaceuticals, Llc	Amorphous kinase inhibitor formulations and methods of use thereof
PL4084779T3 (pl)	2019-12-30	2025-02-24	Deciphera Pharmaceuticals, Llc	Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
KR102535840B1 (ko)	2020-07-31	2023-05-23	(주)파로스아이바이오	2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU1528449A1 (ru) *	1985-06-05	1989-12-15	Центральный институт усовершенствования врачей	Способ релаксации илеоцекального отдела кишечника
TW225528B (pl) *	1992-04-03	1994-06-21	Ciba Geigy Ag
CO4940418A1 (es) *	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP1117397A1 (en) *	1998-08-31	2001-07-25	Sugen, Inc.	Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity

2001
- 2001-10-26 SK SK518-2003A patent/SK287335B6/sk not_active IP Right Cessation
- 2001-10-26 AT AT01988712T patent/ATE321556T1/de active
- 2001-10-26 MX MXPA03003703A patent/MXPA03003703A/es active IP Right Grant
- 2001-10-26 BR BR0114870-2 patent/BRPI0114870B8/pt active IP Right Grant
- 2001-10-26 EP EP01988712A patent/EP1332137B1/en not_active Expired - Lifetime
- 2001-10-26 IL IL15502901A patent/IL155029A0/xx unknown
- 2001-10-26 HU HU0301512A patent/HU229106B1/hu unknown
- 2001-10-26 DE DE60118430T patent/DE60118430T2/de not_active Expired - Lifetime
- 2001-10-26 WO PCT/EP2001/012442 patent/WO2002034727A2/en not_active Ceased
- 2001-10-26 KR KR1020037003903A patent/KR100885129B1/ko not_active Ceased
- 2001-10-26 AU AU1826202A patent/AU1826202A/xx active Pending
- 2001-10-26 AU AU2002218262A patent/AU2002218262B2/en not_active Expired
- 2001-10-26 PT PT01988712T patent/PT1332137E/pt unknown
- 2001-10-26 PL PL362148A patent/PL209733B1/pl unknown
- 2001-10-26 CA CA002424470A patent/CA2424470C/en not_active Expired - Lifetime
- 2001-10-26 RU RU2003114752/15A patent/RU2301066C2/ru not_active IP Right Cessation
- 2001-10-26 US US10/415,015 patent/US6958335B2/en not_active Expired - Lifetime
- 2001-10-26 JP JP2002537718A patent/JP4386635B2/ja not_active Expired - Lifetime
- 2001-10-26 DK DK01988712T patent/DK1332137T3/da active
- 2001-10-26 NZ NZ525254A patent/NZ525254A/en not_active IP Right Cessation
- 2001-10-26 CN CNB018178952A patent/CN1276754C/zh not_active Ceased
- 2001-10-26 ES ES01988712T patent/ES2260317T3/es not_active Expired - Lifetime
- 2001-10-26 CZ CZ20031152A patent/CZ303944B6/cs not_active IP Right Cessation
2003
- 2003-03-18 ZA ZA200302155A patent/ZA200302155B/en unknown
- 2003-03-20 IL IL155029A patent/IL155029A/en active IP Right Grant
- 2003-04-24 NO NO20031833A patent/NO324948B1/no not_active IP Right Cessation
2006
- 2006-06-21 CY CY20061100839T patent/CY1105055T1/el unknown

Also Published As

Publication number	Publication date
PT1332137E (pt)	2006-07-31
US6958335B2 (en)	2005-10-25
ES2260317T3 (es)	2006-11-01
KR100885129B1 (ko)	2009-02-23
JP2004512328A (ja)	2004-04-22
ATE321556T1 (de)	2006-04-15
PL209733B1 (pl)	2011-10-31
JP4386635B2 (ja)	2009-12-16
HUP0301512A2 (hu)	2003-11-28
EP1332137A2 (en)	2003-08-06
EP1332137B1 (en)	2006-03-29
NZ525254A (en)	2006-02-24
CZ20031152A3 (en)	2004-04-14
BRPI0114870B8 (pt)	2021-05-25
NO20031833D0 (no)	2003-04-24
WO2002034727A3 (en)	2003-03-27
NO324948B1 (no)	2008-01-07
WO2002034727A2 (en)	2002-05-02
SK287335B6 (sk)	2010-07-07
SK5182003A3 (en)	2004-02-03
RU2301066C2 (ru)	2007-06-20
AU2002218262B2 (en)	2005-09-29
KR20030051656A (ko)	2003-06-25
CZ303944B6 (cs)	2013-07-10
MXPA03003703A (es)	2005-01-25
IL155029A0 (en)	2003-10-31
CN1276754C (zh)	2006-09-27
CA2424470A1 (en)	2002-05-02
US20040023976A1 (en)	2004-02-05
DE60118430D1 (de)	2006-05-18
BRPI0114870B1 (pt)	2020-06-16
DE60118430T2 (de)	2006-10-26
DK1332137T3 (da)	2006-07-17
HU229106B1 (en)	2013-07-29
CN1622808A (zh)	2005-06-01
HK1058193A1 (en)	2004-05-07
BR0114870A (pt)	2004-02-17
CY1105055T1 (el)	2010-03-03
ZA200302155B (en)	2004-04-22
NO20031833L (no)	2003-04-24
CA2424470C (en)	2009-06-09
IL155029A (en)	2009-09-22
AU1826202A (en)	2002-05-06

Publication	Publication Date	Title
IL155029A0 (en)	2003-10-31	Treatment of gastrointestinal stromal tumors
MY128664A (en)	2007-02-28	Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
IL164678A (en)	2014-02-27	High-drug tablet containing 4– (4-methylpiprazine – 1-ylamethyl) -n - [(4-methyl-3– (4-pyridin-3-il) pyrimidine-2-ylamino) phenyl] -benzamide or compatible salt Its pharmaceutical and process for its preparation
IL177005A0 (en)	2006-12-10	Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
ATE311389T1 (de)	2005-12-15	Wirkstoffvorläufer von imidazopyridin-derivaten
DE60321888D1 (pl)	2008-08-14
BR0316126A (pt)	2005-09-27	Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica
AU2003216621A8 (en)	2003-10-20	Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
IL171927A0 (en)	2006-04-10	Use of tyrosine kinase inhibitor to treat diabetes
WO2004103374A3 (en)	2005-04-14	Imatinib combinations for head and neck cancers
AU2003244922A1 (en)	2004-01-19	4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis
AU2003209521A1 (en)	2003-09-09	Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
AU2003232376A1 (en)	2004-02-09	4-(4-methylpiperazin-1-ylmethyl)-n-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating anaplastic thyroid cancer
NZ610401A (en)	2014-08-29	Inhibitors of the mutant form of kit
HK1097535A (en)	2007-06-29	Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
DE60310896D1 (de)	2007-02-15	PHARMAZEUTISCHE ZUBEREITUNGEN ENTHALTEND NANOPARTIKEL VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANSULPHONYL-PHENYL)-PYRAZOLOi1,5-BöPYRIDAZIN